E10K1

E10K1 is an investigational oncolytic virus therapy being developed by Guangzhou Double Bioproducts (also known as Guangzhou Dabao Bioproducts). As an oncolytic virus, E10K1 is designed to selectively infect and replicate within malignant cells, leading to direct cell lysis (oncolysis). This process releases tumor-associated antigens and pathogen-associated molecular patterns (PAMPs) into the tumor microenvironment, which can stimulate a systemic anti-tumor immune response. E10K1 is part of the company's specialized pipeline of adenovirus-based therapies, which includes other candidates like E10A and E10B. While specific genetic modifications or transgenes for E10K1 have not been widely disclosed in public clinical registries, it is primarily positioned for the treatment of various solid tumors.